Hepatitis C Treatment Reduces the Virus but Liver Damage Continues

December 10, 2008

Treating patients who have chronic hepatitis C and advanced liver disease with long-term pegylated interferon significantly decreased their liver enzymes, viral levels and liver inflammation, but the treatment did not slow or prevent the progression of serious liver disease, a study finds.

These findings come from the clinical trial, Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) and are reported in the Dec. 4 issue of the New England Journal of Medicine. HALT-C was funded by the National Institutes of Health (NIH) with additional support from Hoffmann-La Roche Inc.

"The results from HALT- C show without question that maintenance therapy with peginterferon does not prevent progression of liver disease among patients who have failed prior treatments," said James Everhart, M.D., project scientist for HALT-C in the Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the principal sponsor of HALT-C at NIH. "These findings heighten the incentive to develop more effective drugs for patients with severe liver disease due to hepatitis C."

Peginterferon therapy for up to 48 weeks is standard for chronic hepatitis C. But patients who do not have a sustained response to initial therapy have been given the drug over a longer time based on studies showing that this approach suppresses viral and enzyme levels, even if the virus is not completely eliminated. However, it was not known if long-term therapy would improve important clinical outcomes such as liver damage and death.

HALT-C, a randomized multicenter trial of 1,050 patients with chronic hepatitis C who had failed prior treatment to eradicate the infection, tested whether long-term treatment with peginterferon alfa-2a would reduce the development of cirrhosis, liver cancer, or liver failure. The 517 patients randomized to the treatment arm received 90 micrograms of peginterferon in weekly injections for 3.5 years. The 533 patients in the control arm underwent the same follow-up and care as the treated patients including liver biopsies, quarterly clinic visits and blood tests. All patients had advanced liver fibrosis, a gradual scarring of the liver that puts patients at risk for progressive liver disease and liver failure.

The outcomes studied in HALT-C were death, liver cancer, or liver failure, and for those who did not have cirrhosis initially, the development of cirrhosis. At the end of the study, 34.1 percent of the treated group and 33.8 percent of the control group had experienced at least one outcome. Patients in the treated group had significantly lower blood levels of the hepatitis C virus and improvement in liver inflammation. However, there was no major difference in rates of any of the primary outcomes between the groups.

Among treated patients, 17 percent stopped peginterferon after 18 months and 30 percent stopped the drug after two years. Infections, musculoskeletal or digestive problems were the most common reasons for stopping the drug.

According to HALT-C study chair and principal investigator Adrian M. Di Bisceglie, M.D., professor of internal medicine at Saint Louis University School of Medicine in Missouri, looking into how maintenance therapy works in non-responders is an important step. "Patients should not receive interferon as maintenance therapy for chronic hepatitis C. However, we can build on what was learned in HALT-C to identify better treatments that may delay or prevent liver damage in patients with advanced disease," he said.

The hepatitis C virus infects more than 100 million persons worldwide and as many as 4 million in the United States. Hepatitis C ranks with alcohol abuse as the most common cause of chronic liver disease and leads to about 1,000 liver transplants in the United States each year. The best current antiviral therapy of pegylated interferon given by injection in combination with oral ribavirin for about 6 months to a year eliminates the virus in about 50 percent of infected patients.
The following researchers and clinical centers conducted the HALT-C study:

* Dr. Jules L. Dienstag, Massachusetts General Hospital and Harvard Medical School, Boston, Mass.
* Dr. Adrian M. Di Bisceglie (Study Chair), Saint Louis University School of Medicine, Saint Louis, Mo.
* Dr. Anna S. Lok, University of Michigan Medical Center, Ann Arbor
* Dr. Gyongyi Szabo, University of Massachusetts, Worcester
* Dr. Timothy R. Morgan, University of California, Irvine and VA Long Beach Healthcare System, Long Beach, Calif.
* Gregory T. Everson, University of Colorado Health Sciences Center, Denver
* Dr. Herbert L. Bonkovsky, University of Connecticut Health Center, Farmington.
* Dr. Karen L. Lindsay, Keck School of Medicine, University of Southern California, Los Angeles
* Dr. William M. Lee, University of Texas Southwestern Medical Center, Dallas
* Dr. Mitchell L. Shiffman, Virginia Commonwealth University Medical Center, Richmond
* Dr. Chihiro Morishima and Dr. David Gretch, University of Washington, Seattle
* Dr. Kristin K. Snow, New England Research Institutes, Watertown, Mass.
* Dr. Marc G. Ghany, Liver Diseases Branch, NIDDK, NIH, Bethesda, Md.

For information about liver disease research, see http://www2.niddk.nih.gov/AboutNIDDK/ResearchAndPlanning/Liver_Disease/Action_Plan_For_Liver_Disease_Intro.htm

For consumer-based information about the liver, visit NIDDK's National Digestive Diseases Information Clearinghouse (NDDIC) online at www.digestive.niddk.nih.gov

More information about the HALT-C trial (NCT00252642) can be found at www.clinicaltrials.gov

NIDDK, part of the NIH, conducts and supports basic and clinical research and research training on some of the most common, severe and disabling conditions affecting Americans. The Institute's research interests include diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition, and obesity; and kidney, urologic and hematologic diseases. For more information, visit www.niddk.nih.gov.

The National Institutes of Health (NIH) - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

The National Institutes of Health (NIH)

---

---

	ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS B AND C: Which patients are likely to benefit from which agents? (Postgraduate Medicine) by JTE Multimedia Antiviral therapy in chronic hepatitis can completely eradicate the virus and induce remission of liver disease. To achieve such benefits, however, therapy should be initiated before decompensated liver disease ensues; at that point, liver transplantation is the only available option. In this article, Dr Gordon describes indications for and contraindications to antiviral therapy in chronic hepatitis. He also summarizes relative advantages and drawbacks of the treatment options available at present. Gordon SC. Antiviral therapy for chronic hepatitis B and C: which patients are likely to benefit from which agents? Original Publication Date: February 2000
	DIAGNOSIS AND MANAGEMENT OF CHRONIC HEPATITIS B IN THE PRIMARY CARE SETTING: A better understanding of virology and an increasing number of approved drugs ... serious infection. (Postgraduate Medicine) by JTE Multimedia Abstract: Chronic hepatitis B has affected approximately 350 million people worldwide.1 In the United States, the Centers for Disease Control and Prevention (CDC) report a prevalence of 1.25 million. The incidence of acute hepatitis B has been in decline since the 1980s, as a corollary to preventive efforts against human immunodeficiency virus (HIV) infection in homosexual men and illicit injection drug use, in addition to perinatal screening and vaccination against hepatitis B virus (HBV).2–4 However, because of the increasing influx of immigrants from hepatitis B-endemic areas such as Asian Pacific regions and Eastern Europe, chronic hepatitis B is probably more prevalent than estimated in the United States, particularly on the East and West coasts and in metropolitan cities.
	Chronic hepatitis B.(THE EFFECTIVE PHYSICIAN)(Clinical report): An article from: Internal Medicine News by William E. Golden (Author), Robert H. Hopkins (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on November 1, 2008. The length of the article is 862 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: Chronic hepatitis B.(THE EFFECTIVE PHYSICIAN)(Clinical report) Author: William E. Golden Publication: Internal Medicine News (Magazine/Journal) Date: November 1, 2008 Publisher: International Medical News Group Volume: 41 Issue: 21 Page: 41(1) Article Type: Clinical report Distributed by Gale, a part of Cengage...
	Chronic Hepatitis B: Perceptions in Asian American Communities and Diagnosis and Management Practices Among Primary Care Physicians (Postgraduate Medicine) by JTE Multimedia Asian Americans exhibit a high prevalence of chronic hepatitis B (CHB) compared with the general population in the United States. However, there are specific barriers to appropriate health care in the Asian American population, and CHB awareness is low. The aim of this study was to examine CHB awareness among the Asian American population and to assess the role and attitudes of primary care physicians in CHB diagnosis and treatment, particularly in relation to Asian American communities. Methods Participants from the Asian American community were randomly selected using telephone directories, and completed a questionnaire regarding attitudes toward CHB during telephone interviews. Primary care physicians completed a structured, online questionnaire. Results A total of 610 Asian Americans...
	Chronic Active Hepatitis: The Mayo Clinic Experience (Gastroenterology Series) by Albert J. Czaja (Author), E. Rolland Dickson (Editor)
	The Cure of Chronic Hepatitis B: One Man's Cure One Family's Experience by Kunmi Oluleye (Author), Ibiyinka Oluleye (Author), Ibibyinka Oluleye (Author), Oluleye (Author), Kunmi (Author), Ibiyinka (Author) This is a source of detailed information of the treatment of a Hepatitis B patient. Even though the focus is on Hepatitis B, there's useful information and resources listed for other hepatitis types, especially Hepatitis C. The book is written in journal form to give the readers a complete picture of the authors' experience. Read about the six-month combination treatment of Interferon Alpha-2b and Ribavirin (Virazole). There are tables clearly listing drugs, food intakes, vitamins and homones. A great resource for anyone associated with hepatitis directly or indirectly, every victim, family or friend, hepatologist, nurse or medical student. Be informed about this deadly disease.
	Chronic Hepatitis C Virus: Advances in Treatment, Promise for the Future by Mitchell L. Shiffman (Editor) Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future documents the monumental advances that have been made in our understanding of chronic HCV during the past decade. The first section reviews the natural history of chronic HCV, how this virus can affect other organs in addition to the liver, and whether treating chronic HCV alters the natural history of this disease. Section 2 reviews the advances that have been made in the treatment of chronic HCV during the past decade with interferon based therapy. Separate chapters on response guided therapy and how to manage the adverse events associated with these medications provide the physician with the concepts required to more effectively treat chronic HCV now and in the future. As the genetics of virologic response have...
	Management of Chronic Viral Hepatitis (Gastroenterology and Hepatology) by Stuart Gordon (Author) This up-to-date reference serves as a comprehensive overview of, and patient treatment manual for, chronic viral hepatitis-accounting for subtleties in the diagnosis and treatment of individual patients, rapidly evolving concepts in patient management, and heightened public awareness of the disease. Illustrates how current advances in diagnostic and therapeutic modalities may benefit patients with chronic viral hepatitis! Organized in an easily consulted case-study format that focuses on relevant and challenging patient cases in each chapter, Management of Chronic Viral Hepatitis · reviews the transition from biochemical measurements to therapy based on viral endpoints and direct antivirals · describes emerging treatments for hepatitis B and hepatitis C · navigates through the...
	Chronic Hepatitis B: An Update, An Issue of Clinics in Liver Disease, 1e (The Clinics: Internal Medicine) by Naoky C.S. Tsai MD (Author) A recent Institute of Medicine report has concluded that "there is a lack of knowledge and awareness about chronic viral hepatitis on the part of health-care and social-service providers, as well as among at-risk populations, members of the public, and policy-makers. Due to the insufficient understanding about the extent and seriousness of this public-health problem, inadequate public resources are being allocated to prevention, control, and surveillance programs". It is with these concerns in mind that Dr. Tsai assembled a group of experts in this field to present their expertise in such a level, where the practicing clinicians who deal with this disease in their daily practice can understand thereby implement this knowledge into their own practice. Dr. Brian McMahon discusses the...
	Chronic Viral Hepatitis: Diagnosis and Therapeutics (Clinical Gastroenterology) by Kirti Shetty (Editor), George Y. Wu (Editor), Raymond S. Koff (Editor) Leading scientists, clinicians, and clinical investigators comprehensively review the epidemiology, molecular virology, diagnosis, treatment, and prevention of chronic hepatitis caused by the B and C viruses. The discussion of patient management includes contributions on developing novel therapeutics, supporting patients during therapy, alternative treatments, the use of drugs in chronic viral hepatitis, liver transplantation, and pregnancy in chronic viral hepatitis. Attention is also given to the treatment of patients with concomitant autoimmune disorders, the management of HIV co-infection, and the management of HBV/HCV co-infection.